Company Synthaverse S.A.

Company Synthaverse S.A.

SVE

PLBMDLB00018

Pharmaceuticals

Equities

SVE

PLBMDLB00018

Pharmaceuticals

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Sales per region

Sector Biopharmaceuticals

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Sales per region

Sector Biopharmaceuticals

Market Closed - Warsaw S.E. Other stock markets 09:25:54 09/05/2024 pm IST			5-day change	1st Jan Change
4.81 ^PLN	+2.45%		-2.83%	+12.65%

10/04	Synthaverse S.A. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
2023	Synthaverse S.A. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	CI

Synthaverse SA formerly known as Biomed Lublin Wytwornia Surowic i Szczepionek SA is a Poland-based company operating in the Life Science industry, dealing primarily with the production of medicines. The Company focuses on the production of drugs in the field of immunotherapy. Synthaverse SA offers its services in the field such as: oncological immunotherapy, Immunotherapy in Serological Conflict, Passive immunotherapy in hepatitis B, Active anti-tuberculosis immunotherapy, Gynecology and Proctology, Probiotics, Laboratory reagents. The Company offers injection drugs, lyophilisates of active substances in sterile sealed vials, active substances and drugs based on surface and submerged biological culture, suppository forms of drugs. The Company supplies its products to 50 countries around the world.

Number of employees: 239

PLN in Million	2022	Weight	Delta
Traditional 53.6 %	27	53.6 %	-
BCG 46.4 %	23	46.4 %	-

PLN in Million	2022	Weight	Delta
Poland 52.2 %	26	52.2 %	-
Other Countries 26.3 %	13	26.3 %	-
European Union 21.5 %	11	21.5 %	-

Managers	Title	Age	Since
Mieczyslaw Starkowicz CEO	Chief Executive Officer	-	-
Waldemar Artur Sierocki BRD	Director/Board Member	69	01/08/01
Jakub Tadeusz Winkler LAW	General Counsel	39	01/13/01

Members of the board	Title	Age	Since
Waldemar Artur Sierocki BRD	Director/Board Member	69	01/08/01
Wiktor Napióra BRD	Director/Board Member	68	01/09/01
Dariusz Jan Kucowicz BRD	Director/Board Member	59	01/08/01
Konrad Adam Miterski BRD	Director/Board Member	51	01/17/01
Jaroslaw Pawel Blaszczak CHM	Chairman	51	30/16/30
Dirk Pamperin BRD	Director/Board Member	-	01/20/01
Maciej Korniluk BRD	Director/Board Member	-	-
Maciej Siedlar BRD	Director/Board Member	-	-

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	70,260,410	39,706,866 ( 56.51 %)	0	56.51 %

Name	Equities	%	Valuation
Dariusz Jan Kucowicz 8.016 %	5,653,005	8.016 %	6 M zł
Organizacja Polskich Dystrybutorow Farmaceutycznych SA 7.142 %	5,036,727	7.142 %	5 M zł
Wiktor Napióra 7.009 %	4,942,623	7.009 %	5 M zł
Waldemar Artur Sierocki 6.793 %	4,790,504	6.793 %	5 M zł
Przemyslaw Sierocki 6.785 %	4,785,083	6.785 %	5 M zł
Jaroslaw Pawel Blaszczak 1.796 %	1,266,483	1.796 %	1 M zł
AgioFunds TFI SA 0.1067 %	75,278	0.1067 %	73 810 zł
PKO TFI SA 0.0204 %	14,378	0.0204 %	14 098 zł
Konrad Adam Miterski 0.0127 %	8,959	0.0127 %	8 784 zł
IPOPEMA TFI SA 0.0106 %	7,456	0.0106 %	7 311 zł

Synthaverse SA

ul. Uniwersytecka 10

20-029, Lublin

+48 81 533 8221

http://www.biomedlublin.com

	1st Jan change	Capi.
SYNTHAVERSE S.A.	+12.65%	82.76M
CSL LIMITED	-2.78%	88.91B
SAMSUNG BIOLOGICS CO.,LTD.	+2.76%	41.25B
BIOGEN INC.	-13.92%	31.99B
UCB	+50.51%	24.73B
BIOMARIN PHARMACEUTICAL INC.	-15.25%	15.54B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-39.93%	12.07B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-9.08%	12.05B
INCYTE CORPORATION	-14.80%	12.02B
SWEDISH ORPHAN BIOVITRUM AB	+6.22%	8.84B

Biopharmaceuticals

Healthcare

Pharmaceuticals & Medical Research

Pharmaceuticals

Pharmaceuticals

Biopharmaceuticals